Osteopathic manipulative treatment on Parkinson´s related symptoms

Click to view

Parkinson's disease is the second most prevalent neurodegenerative disorder in the world, and its numbers are growing. Pharmaceutical management remains the primary treatment pathway, but it is increasingly clear that drugs alone cannot address the full range of what the disease takes from a person — or, as Kendra Byers reminds us, from an animal. Horses can develop toxic equine parkinsonism through prolonged ingestion of yellow star thistle or Russian knapweed. Dogs may develop it through hereditary or injury-related pathways. The symptom overlap with human PD is significant, which means the potential value of OMT as a cross-species intervention is worth investigating seriously. Byers structures her review across three domains: pain management, functional mobility, and quality of life. On pain, the picture is encouraging. Around 60% of people living with PD experience pain, most commonly in the lower back — an area where OMT has demonstrated clear efficacy in the broader clinical population. Byers makes a compelling argument that reducing reliance on opioids and NSAIDs, both of which carry serious risks with prolonged use, makes osteopathic management not just clinically interesting but ethically important. The functional findings are equally promising. A single session of whole-body OMT has been shown to increase sagittal hip range of motion in PD patients — meaningful in a condition where reduced joint mobility directly contributes to falls, injury, and loss of independence. Postural stability improvements have also been documented, attributed to reduced muscular rigidity allowing a more upright centre of gravity. Perhaps the most unexpected territory concerns the glymphatic system — the brain's waste-clearance network, dysfunction in which is implicated in both Alzheimer's and PD. OMT's effects on lymphatic and cranial circulation may have a role to play in reducing the toxic protein build-up that drives neurodegeneration. It is a hypothesis still requiring species-specific research, but the mechanistic logic is sound and the early animal data is encouraging. Byers is clear-eyed about the limitations: sample sizes vary, species-specific studies are scarce, and technique classification needs greater consistency across the field. But the overall trajectory of the evidence points toward OMT as a meaningful complementary therapy. For a disease that currently has no cure, that matters considerably.